Evidence map›Paper›PMID 42110531›Full record

ArticleFrontiers in pharmacology2026

Single-dose pharmacokinetics, tolerability, and physiologically based pharmacokinetic modeling of Fazamorexant in Chinese patients with hepatic impairment and in healthy controls.

Qingmei Li, Min Wu, Cuiyun Li, Xingxing Huang, Lu Jin, Wenjuan Deng, Ruwei Wang, Jiajia Mai, Hong Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qingmei LiDepartment of Pediatric Nephrology, Children's Medical Center, The First Hospital of Jilin University, Jilin, China.
Min WuPhase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
Cuiyun LiPhase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
Xingxing HuangYangtze River Pharmaceutical Group Co., Ltd., Taizhou, China.
Lu JinYangtze River Pharmaceutical Group Co., Ltd., Taizhou, China.
Wenjuan DengYangtze River Pharmaceutical Group Co., Ltd., Taizhou, China.
Ruwei WangYangtze River Pharmaceutical Group Co., Ltd., Taizhou, China.
Jiajia MaiPhase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
Hong ZhangPhase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: YZJ-1139 (Fazamorexant) is a dual orexin receptor antagonist in development for adult insomnia. This study assessed the impact of hepatic impairment on Fazamorexant's pharmacokinetic safety, and tolerability to guide clinical dosing. Methods: This study used a non-randomized, open-label, single-dose design. Patients with mild or moderate hepatic impairment (Child-Pugh class A or B) and healthy subjects (n = 8 per group) received a single oral 20 mg dose of Fazamorexant. Results: In total, 24 participants were enrolled and completed the study. In subjects with mild hepatic impairment, the geometric mean ratios (90% CI) of Fazamorexant plasma C Conclusion: Fazamorexant showed good safety and minimal impact of hepatic impairment on C

Indexed as

Fazamorexanthepatic impairmentinsomniapharmacokineticssafetyYZJ-1139

Identifiers

PMID42110531
PMCPMC13153453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.